| Jacqueline Saunders, | |
|
701 Loyola Ave Ste 108, New Orleans, LA 70113-1912 | |
| (504) 503-0878 | |
| (504) 503-0893 |
| Full Name | Jacqueline Saunders |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 701 Loyola Ave Ste 108, New Orleans, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003591611 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 8470 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jacqueline Saunders, Po Box 50159, New Orleans, LA 70150-0159 Ph: (504) 503-0878 | Jacqueline Saunders, 701 Loyola Ave Ste 108, New Orleans, LA 70113-1912 Ph: (504) 503-0878 |
News Archive
Duke University Medical Center scientists crowded around a laser-powered microscope in a darkened room to peer into the brain of an anesthetized juvenile songbird right after he heard an adult tutors' song for the first time.
When a person has a severely damaged cornea, a corneal transplant is required. However, there are 2,000 patients waiting for the cornea donation in the country as of 2018 and they wait for 6 or more years on average for the donation.
Receptos, announced today that their highly selective sphingosine-1-phosphate receptor 1 agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study.
Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: 'Method for terminating methadone maintenance through extinction of the opiate-taking responses', using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
› Verified 8 days ago
Dr. Rebecca Linnea Kendig, PH.D., LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 8620 Jeannette St, New Orleans, LA 70118 Phone: 504-292-1447 | |
Melissa Scheib, CSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4919 Canal St, Suite 203, New Orleans, LA 70119 Phone: 504-483-9883 | |
Sarah Tebbe, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2640 Canal St Ste 4, New Orleans, LA 70119 Phone: 504-821-2232 | |
Ms. Monica Marie Mills-mattox, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1050 S Jeff Davis Pkwy Ste 240, New Orleans, LA 70125 Phone: 832-725-0586 Fax: 888-977-1299 | |
Mrs. Shenicka Adams Varnado, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3801 Canal St, Suite 314, New Orleans, LA 70119 Phone: 504-483-7254 | |
Ms. Sharon Elizabeth Smith, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3519 Chestnut St, New Orleans, LA 70115 Phone: 504-232-9260 |